Comparing the current results to its competitors, Os Therapies Incorporated reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.02 %, recorded in the same quarter.
Os Therapies Incorporated, slower than the average decrease reported by the company's competitors of -74.98 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -74.98 %
Os Therapies Incorporated's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapid technological advancement and evolving regulatory requirements. It faces competition from large pharmaceutical companies, biotechnology firms, academic institutions, government agencies, and other research organizations developing or commercializing therapies for cancer and rare diseases, including Osteosarcoma. While the company is not aware of any adjuvant therapy for pediatric Osteosarcoma more advanced than its OST-HER2 product, several organizations are developing competing therapies. Notable competitors include AstraZeneca, Y-mAbs Therapeutics, and academic institutions such as MD Anderson Cancer Center. Key competitive factors include successful product development, clinical trial safety and efficacy, regulatory approvals, intellectual property protection, manufacturing capabilities, reimbursement, and commercialization success.
Publicly Traded Peers of Os Therapies Incorporated
Vertex Pharmaceuticals Inc Share Performance
+16.49%
30 Days
Vertex Pharmaceuticals Inc
Profile
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Biovie Inc is a biotechnology company that aims to develop advanced therapeutic solutions for various diseases. They have a unique business model that focuses on research and development of innovative drugs, strategic partnerships and collaborations with other organizations, along with potential commercialization of their products to generate revenue. Their goal is to create groundbreaking medical treatments that improve the quality of life for patients.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Calcimedica Inc is a biopharmaceutical company that focuses on the research and development of small molecule drugs to treat a range of diseases caused by calcium dysregulation. Their business model involves identifying potential drug candidates, conducting preclinical and clinical trials, and eventually commercializing these drugs to address unmet medical needs.
Cellectar Biosciences Inc is a biopharmaceutical company that focuses on the development of targeted cancer therapies. They utilize their proprietary drug conjugation platform to create targeted small molecules that can selectively bind and deliver radioactive isotopes directly to cancer cells. Their business model revolves around developing and commercializing these innovative therapies for the treatment of various types of cancer, aiming to improve patient outcomes and potentially revolutionize cancer treatment.
Sources:
Os Therapies Incorporated’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Os Therapies Incorporated versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
